Back to Results
First PageMeta Content
Nucleotides / Purines / Organochlorides / Bristol-Myers Squibb / Clopidogrel / Prodrugs / Antiplatelet drug / Cangrelor / Platelet / Medicine / Chemistry / Organic chemistry


Cangrelor An IV P2Y12 Inhibitor for the Reduction of Thrombotic Events in Patients Undergoing PCI or Requiring Bridging to Surgery Presentation to the Cardiovascular and Renal Advisory Committee
Add to Reading List

Open Document

File Size: 1,97 MB

Share Result on Facebook

City

PHOENIX / /

Company

ACS / The Medicines Company / /

Country

United States / /

Event

FDA Phase / Product Issues / /

MedicalCondition

stent thrombosis / myocardial infarction / /

MedicalTreatment

Surgery / /

Organization

FDA / Cardiovascular and Renal Advisory Committee / /

Position

investigator / Senior Vice President / Program Lead / population representative / /

Product

adenosine / Clopidogrel / patients / CI-8 / US / /

ProgrammingLanguage

D / /

Technology

CAD / /

SocialTag